![GlaxoSmithKline / Pharmacology / Fluticasone/salmeterol / Chronic lower respiratory diseases / Salmeterol / Asthma / Fluticasone propionate / Bronchodilator / Placebo / Medicine / Pulmonology / Respiratory therapy GlaxoSmithKline / Pharmacology / Fluticasone/salmeterol / Chronic lower respiratory diseases / Salmeterol / Asthma / Fluticasone propionate / Bronchodilator / Placebo / Medicine / Pulmonology / Respiratory therapy](https://www.pdfsearch.io/img/69bbab10987600512c1888b27ff62e6e.jpg) GlaxoSmithKline Pharmacology Fluticasone/salmeterol Chronic lower respiratory diseases Salmeterol Asthma Fluticasone propionate Bronchodilator Placebo Medicine Pulmonology Respiratory therapy | | IMPORTANT REVISIONS TO PRESCRIBING INFORMATION FOR SEREVENT® (salmeterol xinafoate) AND ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder) GlaxoSmithKline PO Box 13398Add to Reading ListSource URL: www.fda.govDownload Document from Source Website File Size: 40,29 KBShare Document on Facebook
|